Citigroup Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $17
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $16 to $17.
Citigroup analyst Yigal Nochomovitz maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy and raises the price target from $16 to $17.
